Evidence map›Paper›PMID 35064326›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Sexual and fertility-related adverse effects of medicinal treatment for cancer; a national evaluation among medical oncologists.

E M Krouwel, Z Kramer, R Gordijn, M P J Nicolai, S Osanto, H Putter, R C M Pelger, H W Elzevier

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

E M KrouwelDepartment of Urology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, the Netherlands.
Z KramerDepartment of Urology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, the Netherlands. z.kramer@lumc.nl.ORCID http://orcid.org/0000-0002-6726-2246
R GordijnDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, the Netherlands.
M P J NicolaiDepartment of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, 1066 CX, Amsterdam, the Netherlands.
S OsantoDepartment of Oncology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, the Netherlands.
H PutterDepartment of Medical Statistics, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, the Netherlands.
R C M PelgerDepartment of Urology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, the Netherlands.
H W ElzevierDepartment of Urology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-cancer drugs commonly adversely affect fertility and sexual function. Despite this, patients report a lack of counselling of these potential adverse effects. The aim was to determine Dutch oncologists' knowledge about the adverse effects of various cancer drugs on fertility and sexual function.

methodsA cross-sectional survey was sent to members of the Dutch Society for Medical Oncology (n = 433). The survey questions included various cancer drugs' adverse effects on fertility, ovulation, spermatogenesis, and sexual function.

resultsOne hundred and five of 392 oncologists responded (26.8%). Oncologists were more aware of the adverse effects on fertility compared to sexual function. Drugs that were mostly believed to negatively affect fertility were cisplatin (n = 81, 80.2%), epirubicin (n = 78, 78.0%) and cyclophosphamide (n = 80, 77.7%). Regarding sexual function, most mentioned drugs were tamoxifen (n = 67, 65.7%), GnRH-agonists (n = 64, 63.4%) and cisplatin (n = 58, 57.4%). Oncologists with expertise in urology possessed more awareness regarding sexuality-related adverse effects (cisplatin p = 0.038, etoposide p = 0.025, ifosfamide p = 0.06, vinblastine p = 0.000).

conclusionResults revealed that oncologists have different beliefs about possible sexual and fertility-related adverse effects concerning medication resources and literature. Based on our results, oncologists do not possess sufficient knowledge to inform patients about sexual and fertility-related adverse effects.

Indexed as

NeoplasmsOncologistsAttitude of Health PersonnelCross-Sectional StudiesFemaleFertilityHumansMalePractice Patterns, Physicians'Adverse effectsCancer drugsFertilityOncologyQuality of lifeSexuality

Identifiers

PMID35064326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.